Suchergebnisse - "Rejeski, Kai"

PubPharm (22)

1

Applying the EHA/EBMT grading for ICAHT after CAR-T : comparative incidence and association with infections and mortality

enthalten in: Blood advances | 2024

von Rejeski, K. | Wang, Y. | Hansen, D. | +14

2

Navigating the prognostic role of transfusions after CAR-T

enthalten in: Blood advances | 2024

von Alhomoud, M. | Rejeski, K.

CommentOn: Blood Adv. 2024 Mar 26;8(6):1573-1585. - PMID 38181767

3

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

enthalten in: Blood cancer discovery | 2024

von Faramand, R. | Lee, S. | Jain, M. | +30

4

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Iacoboni, G. | Navarro, V. | Martín-López, A. | +21

5

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells

enthalten in: Neuro-oncology | 2023

von Karschnia, P. | Arrillaga-Romany, I. | Eichler, A. | +24

6

Recognizing, defining, and managing CAR-T hematologic toxicities

enthalten in: Hematology. American Society of Hematology. Education Program | 2023

von Rejeski, K. | Subklewe, M. | Locke, F.

7

Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2023

von Kampouri, E. | Little, J. | Rejeski, K. | +3

8

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

enthalten in: Journal for immunotherapy of cancer | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

9

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

enthalten in: Blood | 2023

von Karschnia, P. | Miller, K. | Yee, A. | +5

CommentIn: Blood. 2023 Oct 5;142(14):1181-1183. - PMID 37796518

10

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

enthalten in: Science advances | 2023

von Rejeski, K. | Perez, A. | Iacoboni, G. | +23